Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UQCRB | P14927 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21086838 | 0.93 | UQCRB (0.86) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL930801 | 0.89 | UQCRB (0.80) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL523563 | 0.89 | UQCRB (0.80) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL27428246 | 0.87 | UQCRB (0.77) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL28178888 | 0.87 | UQCRB (0.77) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL812677 | 0.87 | KMT2A (0.77) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL13480185 | 0.87 | KMT2A (0.77) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL1592323 | 0.87 | UQCRB (0.76) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL13167612 | 0.85 | KMT2A (0.80) | UQCRBMEN1KMT2AALDH1A1PKM | |
| SCHEMBL7824383 | 0.84 | UQCRB (0.72) | UQCRBMEN1KMT2AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751863-B | Terpastacin derivative, preparation method thereof and application thereof in preparation of hypoxia factor inhibitor | 中国科学院南海海洋研究所 | 2024-01-05 | — | — | CN | disclosed |
| CN-115634224-A | Application of Terestacin derivative in preparation of medicine for treating brain glioma | 中国科学院南海海洋研究所 | 2023-01-24 | — | — | CN | disclosed |
| CN-114751863-A | Terestacin derivative, preparation method thereof and application of Terestacin derivative in preparation of low-oxygen factor inhibitor | 中国科学院南海海洋研究所 | 2022-07-15 | — | — | CN | disclosed |
| US-9371286-B2 | Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9371286-B2 | Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-21 | — | — | US | disclosed |
| US-20140315947-A1 | PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315947-A1 | PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2014-10-23 | — | — | US | disclosed |
| US-6921740-B1 | Electron-receiving compound and thermal recording material | MITSUBISHI PAPER MIILS LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-6579829-B2 | Aromatic sulfonamide compound | MITSUI CHEMICALS, INC. (JP) | 2003-06-17 | — | — | US | disclosed |
| EP-1138517-A2 | Developer composition and heat sensitive recording material | Mitsui Chemicals, Inc. (JP) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315947-A1 | PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS | UQCRB, UQCRC1, UQCRC2 | UQCRB 1/4885MEN1 4790/4885KMT2A 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.